PCSK9 inhibitors

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 251-258

  Farnier, Michel ^a  

^a Rond Point de la Nation ^*  (France)

Author keywords

Familial hypercholesterolemia; LDL receptor pathway; LDL cholesterol; Monoclonal antibodies; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; AMG 145; ATORVASTATIN; BMS 84421; BMS 962476; EZETIMIBE; LGT 209; LY 3015014; MONOCLONAL ANTIBODY; PF 04950615; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; RG 7652; RN 316; SERINE PROTEINASE INHIBITOR; SPC 5001; SUBTILISIN; SX PCK 9; SX PCK9; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DEHYDRATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME SYNTHESIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SILENCING; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; MONOTHERAPY; MYOSITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; PROPROTEIN CONVERTASES; PROTEASE INHIBITORS; PROTEIN BINDING; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84880095092     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283613a3d     Document Type: Review

References (51)

1. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein con-vertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003; 100:928-933. (Pubitemid 36183932)
2. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11:367-383.
3. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156. (Pubitemid 36666925)
4. Marduel M, Carrié A, Sassolas A, et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Human Mut 2010; 31:E1811-1824.
5. Cohen J, Pertsemlidis A, Korowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
7. Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55:2833-2842.
8. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperli-pidemia. Focus on therapeutic implications. Am J Cardiovasc Drugs 2011; 11:145-152.
9. Tibolla G, Norata GD, Artali R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011; 21:835-843.
10. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res 2012;53:2515-2524.
11. Rhainds D, Arsenault BJ, Tardif J-C. PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. Clin Lipid 2012; 7:621-640.
12. Surdo PL, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep 2011; 12:1300-1305.
13. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
14. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49:394-398. (Pubitemid 351213624)
15. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51:2717-2721.
16. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersentivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005; 102:5374-5379. (Pubitemid 40530265)
17. Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation 2012; 125:894-901.
18. Hedrick JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Invest Drugs 2009; 10:938-946.
19. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009; 13:19-28.
20. Abifadel M, Pakradouni J, Collin M, et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010; 20:1547-1571.
21. Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hyper-cholesterolemia. Expert Opin Ther Targets 2011; 15:157-168.
22. Marais DA, Blom DJ, Petrides F, et al. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012; 23:511-517.
23. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyper-lipidemic mice. J Lipid Res 2007; 48:763-767. (Pubitemid 46557881)
24. Gupta N, Fisker N, Asselin M-C, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010; 5:e10682.
25. Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA antisense oligonucleo-tides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012; 20:376-381.
26. Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hyper-cholesterolemia. Expert Opin Biol Ther 2013; 13:429-435.
27. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105:11915-11920.
28. Ason B, Tep S, Davis HR Jr, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011; 52:679-687.
29. Fitzgerald K, Frank-Kamenetsky M, Mant T, et al. Phase I safety, pharmaco-kinetic, and pharmacodynamics results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia. Arterioscler Thromb Vasc Biol 2012; 32:A67.
30. Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011; 57:1415-1423.
31. Chan JCY, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterolin mice and nonhuman primates. Proc Natl Acad Sci 2009; 106:9820-9825.
32. Ni YG, Marco S, Condra JH, et al. A PCSK9-binding antibody that structurally mimics the EFG(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011; 52:78-86.
33. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase subtilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012; 340:228-236.
34. Ni YG, Condra JH, Orsatti L, et al. A proprotein convertase subtilisin-like/kexin type 9(PCSK9) C-terminal domain antibody antigene-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010; 285:12882-12891.
35. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-1118.
36. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholester-olemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59:2344-2353.
37. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891-1900.
38. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REG727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380:29-36.
39. Giugliano RP, Desai NR, Kohli P, et al., for the LAPLACE-TIMI 57 investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-con trolled, dose-ranging, phase 2 study. Lancet 2012; 380:2007-2017.
40. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effectsofAMG 145, amonoclonal antibody toproprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417.
41. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380:1995-2006.
42. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS randomized trial. JAMA 2012; 308:2497-2506.
43. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels. J Am Coll Cardiol 2012; 60:1888-1898.
44. Chaparro-Riggers J, Liang H, Devay RM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287:11090-11097.
45. Gumbiner B, Udata C, Joh T, et al. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin. Circulation 2012; 126:A13322.
46. Zhao Z, Tuskli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523. (Pubitemid 44384260)
47. Hopper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193:445-448. (Pubitemid 47058112)
48. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011; 31:785-791.
49. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010; 584:701-706.
50. Stein E, Stender S, Mata P, et al. Ezetimibe Study Group. Achieving lipo-protein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148:447-455. (Pubitemid 39265117)
51. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209:189-194.